ArticleLeukemia research reports2022

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.

Tomoaki Ueda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.